BioSpace News Archive

Orum Therapeutics, a biotechnology company pioneering the development of tumor-directed targeted protein degraders, today announced that the Company will present preclinical data for ORM-5029 at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022 taking place April 8-13 virtually and in-person at the Ernest N. Morial Convention Center in New Orleans.

Nuvalent, Inc., (Nasdaq: NUVL) a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced multiple preclinical data presentations supporting advancement of its parallel lead programs including NVL-520 – a ROS1-selective inhibitor – and NVL-655 – an ALK-selective inhibitor.

Kinnate Biopharma Inc. announced abstracts highlighting the company’s lead RAF kinase inhibitor program, KIN-2787, have been accepted for presentation at the upcoming American Association for Cancer Research Annual Meeting 2022, to be held April 8-13, in New Orleans, Louisiana.

Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), today announced that two abstracts on BMF-219 have been accepted for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022.

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the results from six preclinical studies of the company’s five drug candidates: the Bcl-2 inhibitor lisaftoclax (APG-2575) and the MDM2-p53 inhibitor alrizomadlin (APG-115).

Caribou Biosciences, Inc. (Nasdaq: CRBU), today announced that preclinical data from CB-011, its allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma (r/r MM), will be presented as a poster at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022, held April 8-13, 2022 in New Orleans.

Travere Therapeutics, Inc. announced the pricing of its underwritten offering of $275 million aggregate principal amount of 2.25% convertible senior notes due 2029.

Albany NY, United States: The point-of-care diagnostics market is expected to observe good growth prospects during the forecast period of 2016-2024.

Albany NY, United States: According to a recent study by Transparency Market Research, the global prepacked chromatography columns market has an extremely consolidated vendor landscape, with only two companies accounting for a lion’s share in the overall market.

Albany NY, United States: The global ultraviolet germicidal irradiation market is estimated to witness a decent growth in the span of coming years.